<DOC>
	<DOCNO>NCT02740712</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetic concentration multiple probe alone follow assessment drug pharmacokinetic concentration patient steady-state exposure rucaparib follow cycle-by-cycle treatment rucaparib continue disease progression reason discontinuation .</brief_summary>
	<brief_title>Pharmacokinetic Drug-Drug Interaction Study Rucaparib</brief_title>
	<detailed_description>This Phase 1 , open-label , sequential , drug-drug-interaction ( DDI ) study patient advance solid tumor . The study consist 2 part : DDI part ( Part I ) rucaparib treatment part ( Part II ) . In Part I , PK cytochrome P450 ( CYP ) cocktail probe : caffeine , S-warfarin , omeprazole , midazolam P-glycoprotein probe ( digoxin ) assess without rucaparib treatment . Patients receive single dos CYP drug cocktail ( caffeine , warfarin , omeprazole , midazolam ) Day 1 Day 12 , single dos digoxin Day 2 Day 13 . Continuous treatment 600 mg rucaparib twice daily ( BID ) start Day 5 last least Day 16 Part I . In Part II , treatment rucaparib 28-day cycle continue progression disease , unacceptable toxicity , reason discontinuation .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor Have evidence measurable disease define RECIST Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , renal , liver function Prior treatment chemotherapy , radiation , antibody therapy immunotherapy , gene therapy , vaccine therapy , angiogenesis inhibitor , experimental drug within 14 day prior Day 1 Prior treatment poly adenosine diphosphate ribose polymerase inhibitor ( PARPi ) Arterial venous thrombus ( include cerebrovascular accident ) , myocardial infarction , admission unstable angina , cardiac angioplasty , stenting poorly control hypertension within last 3 month prior Screening ; Preexisting duodenal stent , recent exist bowel obstruction , and/or gastrointestinal disorder defect would , opinion Investigator , interfere absorption study drug Current use therapeutic anticoagulation ( low molecular weight heparin , oral anticoagulant agent include acetylsalicylic acid ) , Current use one probe drug ; Untreated symptomatic central nervous system ( CNS ) metastases . Evidence history bleed disorder Participation another investigational drug trial within 30 day prior Day 1 ( 5 time halflife drug , whichever long ) exposure three new investigational agent within 12 month prior Day 1 ; Acute illness within 14 day prior Day 1 unless mild severity approve Investigator Sponsor 's medical representative Active second malignancy , i.e. , patient know potentially fatal cancer present may ( necessarily ) currently receive treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rucaparib</keyword>
	<keyword>CO-338</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis Oncology</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>Drug-Drug Interaction</keyword>
</DOC>